Erschienen in:
01.09.2012 | Short Communication
Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition
verfasst von:
Milena Perez Mak, Verônica Torres da Costa e Silva, Regina Matsunaga Martin, Antonio Marcondes Lerario, Luis Yu, Paulo Marcelo Gehm Hoff, Gilberto de Castro Junior
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 9/2012
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures.
Result
We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO.
Conclusion
This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.